Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SC291 · 2 trials · 8 indications
Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities
| Arm | Type | Description |
|---|---|---|
| LN Cohort | EXPERIMENTAL | SC291 with lymphodepleting therapy |
| ERL Cohort | EXPERIMENTAL | SC291 with lymphodepleting therapy |
| AAV Cohort | EXPERIMENTAL | SC291 with lymphodepleting therapy |
| SC291 Plus Chemotherapy Regimen | EXPERIMENTAL | A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with SC291 |
| Name | Type | Description |
|---|---|---|
| SC291 | BIOLOGICAL | SC291 is an allogeneic CAR T cell therapy |
Inclusion Criteria: 1. Age ≥18 and ≤75 2. For LN cohort: * Diagnosis of SLE based on the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) * Biopsy-proven LN class III or IV, according to 2018 Revised International Society of Nephrology/Renal Pathology So...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
SC291 is an investigational monoclonal antibody being studied for use in lupus erythematosus and non-Hodgkin lymphoma. It is also being evaluated in chronic lymphocytic leukemia and certain B-cell mediated autoimmune diseases, including systemic lupus erythematosus and ANCA-associated vasculitis.
SC291 is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. The drug is being studied in B-cell mediated diseases, suggesting it may affect B cells, but the exact target is not specified.
SC291 is being developed by Sana Biotechnology, Inc., a company traded under the ticker SANA. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with certain B-cell malignancies and autoimmune diseases.
SC291 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The drug is currently being studied in early-stage trials to assess its safety, tolerability, and preliminary efficacy in humans.
SC291 is being evaluated in two Phase 1 trials. NCT05878184, called ARDENT, is studying the drug in patients with relapsed or refractory B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia. NCT06294236, called GLEAM, is studying it in patients with severe B-cell mediated autoimmune diseases, including lupus erythematosus.
SC291 is not known to have any alternative names. It is a unique investigational drug candidate developed by Sana Biotechnology. No other names or aliases for this drug have been reported in the available information.